• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组织学亚型对接受根治性放疗的局部晚期宫颈癌患者生存的影响:腺癌/腺鳞癌与鳞状细胞癌的比较。

Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.

作者信息

Yokoi Eriko, Mabuchi Seiji, Takahashi Ryoko, Matsumoto Yuri, Kuroda Hiromasa, Kozasa Katsumi, Kimura Tadashi

机构信息

Department of Obstetrics and Gynecology, Osaka University, Graduate School of Medicine, Osaka, Japan.

出版信息

J Gynecol Oncol. 2017 Mar;28(2):e19. doi: 10.3802/jgo.2017.28.e19. Epub 2016 Dec 8.

DOI:10.3802/jgo.2017.28.e19
PMID:28028992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5323286/
Abstract

OBJECTIVE

To compare the survival outcomes of patients with cervical squamous cell carcinoma (SCC) and adenocarcinoma/adenosquamous carcinoma (AC/ASC) among patients with locally advanced cervical cancer that were treated with definitive radiotherapy.

METHODS

The baseline characteristics and outcome data of patients with locally advanced cervical cancer who were treated with definitive radiotherapy between November 1993 and February 2014 were collected and retrospectively reviewed. A Cox proportional hazards regression model was used to investigate the prognostic significance of AC/ASC histology.

RESULTS

The patients with AC/ASC of the cervix exhibited significantly shorter overall survival (OS) (p=0.004) and progression-free survival (PFS) (p=0.002) than the patients with SCC of the cervix. Multivariate analysis showed that AC/ASC histology was an independent negative prognostic factor for PFS. Among the patients who displayed AC/ASC histology, larger tumor size, older age, and incomplete response to radiotherapy were found to be independent prognostic factors. PFS was inversely associated with the number of poor prognostic factors the patients exhibited (the estimated 1-year PFS rates; 100.0%, 77.8%, 42.8%, 0.0% for 0, 1, 2, 3 factors, respectively).

CONCLUSION

Locally advanced cervical cancer patients with AC/ASC histology experience significantly worse survival outcomes than those with SCC. Further clinical studies are warranted to develop a concurrent chemoradiotherapy (CCRT) protocol that is specifically tailored to locally advanced cervical AC/ASC.

摘要

目的

比较接受根治性放疗的局部晚期宫颈癌患者中宫颈鳞状细胞癌(SCC)与腺癌/腺鳞癌(AC/ASC)患者的生存结局。

方法

收集并回顾性分析1993年11月至2014年2月期间接受根治性放疗的局部晚期宫颈癌患者的基线特征和结局数据。采用Cox比例风险回归模型研究AC/ASC组织学的预后意义。

结果

宫颈AC/ASC患者的总生存期(OS)(p = 0.004)和无进展生存期(PFS)(p = 0.002)显著短于宫颈SCC患者。多因素分析显示,AC/ASC组织学是PFS的独立负性预后因素。在表现为AC/ASC组织学的患者中,肿瘤体积较大、年龄较大以及放疗反应不完全是独立的预后因素。PFS与患者表现出的不良预后因素数量呈负相关(估计的1年PFS率;0、1、2、3个因素分别为100.0%、77.8%、42.8%、0.0%)。

结论

组织学为AC/ASC的局部晚期宫颈癌患者的生存结局明显差于SCC患者。有必要开展进一步的临床研究,以制定专门针对局部晚期宫颈AC/ASC的同步放化疗(CCRT)方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3c8/5323286/1305031079a9/jgo-28-e19-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3c8/5323286/4f9791217af6/jgo-28-e19-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3c8/5323286/1305031079a9/jgo-28-e19-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3c8/5323286/4f9791217af6/jgo-28-e19-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3c8/5323286/1305031079a9/jgo-28-e19-g002.jpg

相似文献

1
Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.组织学亚型对接受根治性放疗的局部晚期宫颈癌患者生存的影响:腺癌/腺鳞癌与鳞状细胞癌的比较。
J Gynecol Oncol. 2017 Mar;28(2):e19. doi: 10.3802/jgo.2017.28.e19. Epub 2016 Dec 8.
2
Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy.局部晚期腺癌/腺鳞癌与宫颈鳞癌根治性放疗的临床特征、疗效及预后差异。
Acta Obstet Gynecol Scand. 2014 Jul;93(7):661-8. doi: 10.1111/aogs.12383. Epub 2014 Apr 22.
3
Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.根治性子宫切除术及辅助放疗或放化疗治疗宫颈腺癌或腺鳞癌的临床行为和结局。
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):420-7. doi: 10.1016/j.ijrobp.2011.12.013. Epub 2012 Feb 24.
4
Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis.根治性放疗后子宫颈鳞状细胞癌、腺癌和腺鳞癌临床结局的比较:一项基于人群的分析。
J Cancer Res Clin Oncol. 2017 Jan;143(1):115-122. doi: 10.1007/s00432-016-2246-9. Epub 2016 Sep 19.
5
Comparison of clinical behaviors and responses to radiation between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas of the cervix.子宫颈鳞状细胞癌与腺癌/腺鳞癌的临床行为及对放疗反应的比较。
Chang Gung Med J. 2000 Jul;23(7):396-404.
6
Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.伴有危险因素的ⅠB - ⅡB期宫颈腺癌根治术后的辅助治疗。
Jpn J Clin Oncol. 2017 Jan;47(1):32-38. doi: 10.1093/jjco/hyw145. Epub 2016 Sep 27.
7
Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: a multicenter retrospective study (KROG 13-10).比较接受手术切除后放疗的宫颈癌患者中腺癌和腺鳞癌的临床结局:一项多中心回顾性研究(KROG 13-10)。
Gynecol Oncol. 2014 Mar;132(3):618-23. doi: 10.1016/j.ygyno.2014.01.043. Epub 2014 Jan 31.
8
Treatment outcomes of locally advanced cervical cancer by histopathological types in a single institution: A propensity score matching study.单中心研究:不同组织学类型局部晚期宫颈癌的治疗结局:倾向评分匹配研究。
J Formos Med Assoc. 2018 Oct;117(10):922-931. doi: 10.1016/j.jfma.2018.07.002. Epub 2018 Jul 17.
9
Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma.腺鳞组织学特征预示晚期宫颈癌患者预后不良,但早期宫颈癌患者并非如此。
Cancer. 2003 May 1;97(9):2196-202. doi: 10.1002/cncr.11371.
10
Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stage IB-IIA cervical cancer following radical surgery.比较 FIGO 分期 IB-IIA 期宫颈癌根治术后中国患者腺癌和腺鳞癌的预后。
BMC Cancer. 2020 Jul 16;20(1):664. doi: 10.1186/s12885-020-07148-x.

引用本文的文献

1
Clinical profile and immediate outcomes of concurrent chemoradiation for cervical cancer at the Bugando medical centre in Mwanza, Tanzania.坦桑尼亚姆万扎布甘多医疗中心宫颈癌同步放化疗的临床特征及近期疗效
Afr Health Sci. 2025 Jun;25(2):218-226. doi: 10.4314/ahs.v25i2.27.
2
Value of adjuvant chemotherapy in IB-lIA cervical adenocarcinoma: A multicenter retrospective study.辅助化疗在IB-IIA期宫颈腺癌中的价值:一项多中心回顾性研究。
Chin Med J (Engl). 2025 Sep 5;138(17):2192-2194. doi: 10.1097/CM9.0000000000003693. Epub 2025 Jul 30.
3
Dual functions of the ΔNp63-miR-141-3p-YAP1 regulatory axis in cervical cancer progression are dependent on histological subtype.

本文引用的文献

1
Prognosis of Cervical Cancer in the Era of Concurrent Chemoradiation from National Database in Korea: A Comparison between Squamous Cell Carcinoma and Adenocarcinoma.韩国国家数据库中同步放化疗时代宫颈癌的预后:鳞状细胞癌与腺癌的比较
PLoS One. 2015 Dec 14;10(12):e0144887. doi: 10.1371/journal.pone.0144887. eCollection 2015.
2
Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.奈达铂同步放化疗治疗国际妇产科联盟(FIGO)IB2-IVA期宫颈癌的疗效与安全性及其临床预后因素
J Radiat Res. 2015 Mar;56(2):305-14. doi: 10.1093/jrr/rru101. Epub 2014 Nov 26.
3
ΔNp63-miR-141-3p-YAP1调控轴在宫颈癌进展中的双重功能取决于组织学亚型。
Sci Rep. 2025 Jul 2;15(1):23155. doi: 10.1038/s41598-025-07237-6.
4
The Sensitive Genes for Cervical Cancer: Two-Sample Mendelian Randomization with Experimental Validation.宫颈癌的敏感基因:基于实验验证的两样本孟德尔随机化研究
Int J Womens Health. 2025 May 26;17:1511-1532. doi: 10.2147/IJWH.S516444. eCollection 2025.
5
Construction and validation of nomograms for predicting overall survival and cause-specific survival in cervical cancer patients undergoing radical radiotherapy based on the SEER database.基于监测、流行病学和最终结果(SEER)数据库构建和验证用于预测接受根治性放疗的宫颈癌患者总生存期和特定病因生存期的列线图。
Front Med (Lausanne). 2025 Apr 29;12:1587465. doi: 10.3389/fmed.2025.1587465. eCollection 2025.
6
A Chinese prospective cohort research developed and validated a risk prediction model for patients with cervical cancer.一项中国前瞻性队列研究开发并验证了一种针对宫颈癌患者的风险预测模型。
Cancer Cell Int. 2025 Apr 13;25(1):142. doi: 10.1186/s12935-025-03744-8.
7
The deep learning radiomics nomogram helps to evaluate the lymph node status in cervical adenocarcinoma/adenosquamous carcinoma.深度学习放射组学列线图有助于评估宫颈腺癌/腺鳞癌中的淋巴结状态。
Front Oncol. 2024 Dec 13;14:1414609. doi: 10.3389/fonc.2024.1414609. eCollection 2024.
8
Comparison of Survival Between Different Histological Subtypes in Cervical Cancer Patients: A Retrospective and Propensity Score-matched Analysis.宫颈癌患者不同组织学亚型的生存比较:一项回顾性和倾向评分匹配分析
J Cancer. 2024 Oct 14;15(19):6326-6335. doi: 10.7150/jca.100653. eCollection 2024.
9
Development and validation of the competing risk nomogram and risk classification system for predicting cancer-specific mortality in patients with cervical adenosquamous carcinoma treated via radical hysterectomy.用于预测接受根治性子宫切除术治疗的宫颈腺鳞癌患者癌症特异性死亡率的竞争风险列线图和风险分类系统的开发与验证。
Biomol Biomed. 2025 Apr 3;25(5):1099-1110. doi: 10.17305/bb.2024.11217.
10
Ovarian Metastasis from Human Papillomavirus-associated Usual-type Endocervical Adenocarcinoma: Clinicopathological Characteristics for Distinguishing from Primary Ovarian Mucinous or Endometrioid Tumor.人乳头瘤病毒相关普通型宫颈内膜腺癌的卵巢转移:与原发性卵巢黏液性或子宫内膜样肿瘤鉴别的临床病理特征。
In Vivo. 2024 Jul-Aug;38(4):1973-1983. doi: 10.21873/invivo.13654.
Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation.
在妇科肿瘤学组基于顺铂的同步放化疗试验中,宫颈局部晚期腺癌和腺鳞癌与宫颈鳞状细胞癌的比较
Gynecol Oncol. 2014 Nov;135(2):208-12. doi: 10.1016/j.ygyno.2014.08.018. Epub 2014 Aug 23.
4
Prognosis of adenosquamous carcinoma compared with adenocarcinoma in uterine cervical cancer: a systematic review and meta-analysis of observational studies.子宫颈癌中腺鳞癌与腺癌预后的比较:观察性研究的系统评价和荟萃分析。
Int J Gynecol Cancer. 2014 Feb;24(2):289-94. doi: 10.1097/IGC.0000000000000063.
5
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.宫颈癌中的致癌突变:宫颈癌腺癌和鳞癌的基因组差异。
Cancer. 2013 Nov 1;119(21):3776-83. doi: 10.1002/cncr.28288. Epub 2013 Aug 23.
6
Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).Temsirolimus(CCI-779)治疗复发性、不可切除、局部晚期或转移性宫颈癌的 II 期研究。NCIC 临床试验组(NCIC CTG IND 199)的一项试验。
Gynecol Oncol. 2013 Aug;130(2):269-74. doi: 10.1016/j.ygyno.2013.05.008. Epub 2013 May 11.
7
Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.手术治疗的 IB1 期-IIB 期宫颈癌伴中危或高危因素患者中,同期放化疗对盆腔放疗的影响:13 年经验。
Int J Gynecol Cancer. 2013 Mar;23(3):567-75. doi: 10.1097/IGC.0b013e31828703fd.
8
Comparison of the prognoses of FIGO stage I to stage II adenosquamous carcinoma and adenocarcinoma of the uterine cervix treated with radical hysterectomy.比较 FIGO 分期 I 期至 II 期宫颈腺鳞癌和腺癌患者接受根治性子宫切除术的预后。
Int J Gynecol Cancer. 2012 Oct;22(8):1389-97. doi: 10.1097/IGC.0b013e31826b5d9b.
9
Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma.组织学亚型对手术治疗的 IA2-IIB 期宫颈癌患者生存的影响:腺癌与鳞癌。
Gynecol Oncol. 2012 Oct;127(1):114-20. doi: 10.1016/j.ygyno.2012.06.021. Epub 2012 Jun 21.
10
Nedaplatin: a radiosensitizing agent for patients with cervical cancer.奈达铂:一种用于宫颈癌患者的放射增敏剂。
Chemother Res Pract. 2011;2011:963159. doi: 10.1155/2011/963159. Epub 2010 Sep 21.